A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
Principal Investigator
Melody Cobleigh, MD
Status
Terminated
Date Opened To Accrual
November 10 2008
Date Closed to Accrual
December 08 2014
Date of Study Termination
June 02 2025
Disease Site
Breast [BR]
Breast
Phase
III
Developmental Therapeutics
No
Primary Objective
To determine the value of trastuzumab given during radiation therapy (RT) compared to RT alone in preventing the subsequent occurrence of ipsilateral breast cancer recurrence, ipsilateral skin cancer recurrence, or ipsilateral DCIS
(IIBCR-SCR-DCIS) in women with HER2-positive DCIS resected by lumpectomy.
Patient Population
Women with HER2-positive ductal carcinoma in situ (DCIS) resected by lumpectomy
Target Accrual
2000
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.